Alaunos Therapeutics, Inc.
TCRTHealthcare|Biotechnology|US
$1.74
-0.10 (-5.43%)
DCF Value
$0.33
Tangible Book / Share
$0.27
Cash / Share
$0.05
Clinical Trials (41)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01492036 Long-Term Follow-Up of Recipient of Gene Transfer Research | Retroviridae Infections, Cancer | Recruiting | 130 | — | — | |
| NCT01555710 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) | Extensive-Stage Small Cell Lung Cancer | P3 | Terminated | 188 | RCT, Open-label | Carboplatin, Palifosfamide-tris, Etoposide, Carboplatin |
| NCT01168791 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma | Soft Tissue Sarcoma | P3 | Terminated | 447 | RCT, Double-blind | Palifosfamide-Tris, doxorubicin, Placebo |
| NCT03330197 A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma | P1P2 | Terminated | 6 | Open-label | Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG) |
| NCT01703754 Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | Breast Cancer Nos Metastatic Recurrent | P2 | Terminated | 12 | RCT, Open-label | Palifosfamide |
| NCT00423644 A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | Multiple Myeloma | P2 | Completed | 17 | Open-label | Darinaparson |
| NCT00439686 Study of ZIO-201 in Advanced Sarcoma | Advanced Sarcoma | P1P2 | Completed | 54 | Open-label | ZIO-201 |
| NCT02423902 A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Metastatic Breast Cancer | P1P2 | Terminated | 9 | Open-label | Ad-RTS-hIL-12, Veledimex |
| NCT00421213 Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | Hematologic Neoplasms, Bone Marrow Neoplasms | P2 | Terminated | 50 | Open-label | Darinaparsin |
| NCT05194735 Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | Gynecologic Cancer, Colorectal Cancer | P1P2 | Terminated | 8 | Open-label | Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) |
| NCT01397708 Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | Melanoma | P1P2 | Completed | 26 | Open-label | INXN-2001, INXN-1001 |
| NCT00303199 Study of ZIO-101 in Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 35 | Open-label | ZIO-101 (Darinaparsin) |
| NCT04006119 Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Glioblastoma | P2 | Terminated | 40 | Open-label | Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc |
| NCT00423306 A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | P2 | Terminated | 15 | Open-label | Darinaparsin |
| NCT01808534 Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | Adult Central Nervous System Germ Cell Tumor, Adult Teratoma | P2 | Terminated | 5 | Open-label | palifosfamide |
| NCT00718484 A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma | Soft Tissue Sarcoma | P2 | Terminated | 67 | RCT, Open-label | Palifosfamide-Tris, Doxorubicin |
| NCT00968760 CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | Lymphoma, B-cell Lymphoma | P1 | Completed | 34 | Open-label | IL-2, Carmustine, Etoposide, Cytarabine, Melphalan |
| NCT00591292 Phase I Study in Advanced Solid Tumors | Solid Tumors | P1 | Completed | 22 | Open-label | indibulin |
| NCT00591422 Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas | Advanced Cancer | P1 | Completed | 23 | Open-label | ZIO-101-C (Darinaparsin) |
| NCT00591383 Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 10 | Open-label | indibulin, erlotinib |
| NCT03636477 A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Glioblastoma | P1 | Completed | 21 | Open-label | Ad-RTS-hIL-12, veledimex, Nivolumab |
| NCT00421135 A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer | Advanced Cancer | P1 | Completed | 30 | Open-label | ZIO-201 |
| NCT00607711 Study of Oral Palifosfamide Tris in Solid Tumors | Advanced Cancer | P1 | Withdrawn | — | Open-label | oral palifosfamide tris |
| NCT01113970 Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | Metastatic Breast Cancer | P1 | Terminated | 35 | Open-label | Indibulin |
| NCT01242072 Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | Malignancy, Cancer | P1 | Completed | 22 | Open-label | palifosfamide-tris |
| NCT00591890 Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans | Advanced Cancer | P1 | Completed | 20 | Open-label | indibulin |
| NCT00726687 Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 7 | Open-label | indibulin, capecitabine |
| NCT01139359 Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | Lymphoma | P1 | Withdrawn | — | Open-label | darinaparsin, CHOP |
| NCT01139346 Study of Oral Darinaparsin in Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 12 | Open-label | darinaparsin |
| NCT03679754 Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | Glioblastoma | P1 | Completed | 36 | Open-label | Ad-RTS-hIL-12, veledimex |
| NCT00815607 Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma | Melanoma | P1 | Completed | 12 | Open-label | INXN-1001, INXN-3001 |
| NCT00608803 Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | Advanced Cancer | P1 | Completed | 30 | Open-label | ZIO-201-T and doxorubicin |
| NCT01340547 Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 24 | Open-label | palifosfamide-tris, Normal Saline |
| NCT00592163 Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | Advanced Solid Tumors, Lymphomas | P1 | Completed | 20 | Open-label | ZIO-101-C (Darinaparsin) |
| NCT00591396 A Phase I Trial of ZIO-101 in Solid Tumors | Solid Tumors | P1 | Completed | 40 | Open-label | ZIO-101 (Darinaparsin) |
| NCT00509782 Phase I Trial of ZIO-101 in Patients With Solid Tumors | Solid Tumors | P1 | Completed | 47 | Open-label | ZIO-101 |
| NCT00591136 Phase I Study of Indibulin in Patients With Solid Tumors | Solid Tumors | P1 | Completed | 47 | Open-label | indibulin |
| NCT00592046 A Phase I Trial of ZIO-101 in Hematologic Cancers | Acute Leukemia, Chronic Myeloproliferative Disease | P1 | Completed | 12 | Open-label | ZIO-101 (Darinaparsin) |
| NCT02026271 A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | P1 | Completed | 40 | Open-label | Ad-RTS-hIL-12, veledimex |
| NCT05292859 Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | Gynecologic Cancer, Colorectal Cancer | Completed | 8 | — | Neoantigen specific TCR-T cell drug product | |
| NCT05124743 HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | Ovarian Cancer, Endometrial Cancer | Terminated | 19 | — | — |